Drug Profile
Rosuvastatin/valsartan - LG Chem
Alternative Names: Rovatitan; Valsartan/rosuvastatin; VRLatest Information Update: 07 Feb 2019
Price :
$50
*
At a glance
- Originator LG Life Sciences
- Developer LG Chem; Merck Ltd. Korea
- Class Antihyperlipidaemics; Antihypertensives; Branched-chain amino acids; Fluorobenzenes; Pyrimidines; Small molecules; Sulfonamides; Tetrazoles
- Mechanism of Action Angiotensin type 1 receptor antagonists; HMG-CoA reductase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Hyperlipidaemia; Hypertension
Most Recent Events
- 07 Feb 2019 Chemical structure information added
- 31 Mar 2013 LG Life Sciences completes a phase III trial in Hypertension & hyperlipidaemia in South Korea (NCT01918332)
- 31 Jan 2013 LG Life Sciences completes a phase I bioequivalence trial for Hypertension & hyperlipidaemia (in volunteers) in South Korea (NCT01918358)